# Study of Danicopan in Participants With Hepatic Impairment

> **NCT03555539** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Danicopan

## Key facts

- **NCT ID:** NCT03555539
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2018-09-21
- **Final completion:** 2018-09-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555539, "Study of Danicopan in Participants With Hepatic Impairment". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT03555539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*